KLHL10 Activators

Proteasome inhibitors such as MG132, Epoxomicin, Bortezomib, Lactacystin, and Velcade share a common mechanism of action that involves the blockade of the proteasome's proteolytic functions. This inhibition results in the accumulation of proteins within the cell due to the reduced degradation of ubiquitin-tagged proteins. Such an increase in protein levels could extend to KLHL10, leading to its enhanced presence and activity within the cellular milieu. The accumulation of KLHL10, as a consequence of proteasome inhibition, facilitates its sustained action in the cell, potentially allowing it to more effectively participate in its native cellular processes such as protein-protein interactions or ubiquitin-mediated signaling pathways.

MLN4924, PYR-41, and IU1 target the ubiquitination process itself. MLN4924 inhibits the NEDD8-activating enzyme, disrupting the neddylation process that is crucial for the function of cullin-RING ubiquitin ligases, thus potentially leading to a stabilization of KLHL10. PYR-41 impedes the ubiquitin-activating enzyme E1, curtailing the ubiquitination cascade at its very beginning. IU1 specifically inhibits the deubiquitinase USP14, associated with the proteasome, which could result in an increased concentration of ubiquitinated KLHL10, effectively boosting its activity due to reduced deubiquitination. Chloroquine, known for its role in autophagy inhibition, might also contribute to the stabilization of cellular proteins, including KLHL10, by preventing their lysosomal degradation. ALLN, a calpain inhibitor with proteasome inhibitory properties, further contributes to the enhanced stability of proteins within the cell, potentially affecting the turnover rate of KLHL10. LiCl and SB216763, which inhibit GSK-3, can lead to a decrease in the ubiquitination and subsequent degradation of GSK-3 substrates.